MeiraGTx (MGTX) vs Odyssey Therapeutics (ODTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
MeiraGTx is the larger company by market cap ($1.04 billion vs $868.9 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MGTX | ODTX |
|---|---|---|
| Share price | $10.82 | $18.08 |
| Market cap | $1.04B | $868.90M |
| 1-day change | +2.08% | -0.28% |
| YTD return | +36.10% | — |
| 1-year return | +27.44% | — |
| 5-year return | -24.23% | — |
| P/E ratio (TTM) | 12.44 | — |
| EPS (TTM) | $0.87 | $-7.55 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $15.35 | $29.05 |
| 52-week low | $6.62 | $15.10 |
| Distance from 52-week high | -29.51% | -37.76% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +156.47% | +97.73% |
| Average volume | 797.37K | 270.92K |
| Shares outstanding | 96.04M | 48.06M |
| Employees | 393 | 100 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About MeiraGTx
MGTX stock →MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 393 employees
About Odyssey Therapeutics
ODTX stock →Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of interferon regulatory factor 5 (IRF5); OD-003, a protein therapeutic designed to agonize tumor necrosis factor receptor 2 selectively on Treg; a TSLP/IL-33 bispecific antagonist; an oral small molecule interleukin-1 receptorassociated kinase 4 scaffolding inhibitor; and a small molecule inhibitor of IRF5.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 100 employees
MGTX vs ODTX FAQ
Which is bigger, MeiraGTx or Odyssey Therapeutics?
MeiraGTx (MGTX) is larger, with a market capitalization of $1.04B compared with $868.90M for Odyssey Therapeutics (ODTX).
Are MeiraGTx and Odyssey Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.